Kintara Therapeutics News

KTRADelisted Stock  USD 6.30  0.14  2.17%   
About 62% of Kintara Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Kintara Therapeutics suggests that many traders are alarmed regarding Kintara Therapeutics' prospects. The current market sentiment, together with Kintara Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Kintara Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
over a month ago at investors.com         
Amphastar Pharm Joins Elite List Of Stocks With 95-Plus Composite Rating
Investors Business Daily at Macroaxis
over two months ago at finance.yahoo.com         
Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger w...
Yahoo News
over two months ago at finance.yahoo.com         
Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Spl...
Yahoo News
over two months ago at investors.com         
IBD Rating Upgrades Amphastar Pharm Flashes Improved Relative Price Strength
Investors Business Daily at Macroaxis
over two months ago at seekingalpha.com         
Kintara stock climbs 10 percent on TuHURA merger update
seekingalpha News
over two months ago at thelincolnianonline.com         
Kintara Therapeutics, Inc. Short Interest Update
news
over two months ago at finance.yahoo.com         
Innovent and ASK Pharm to commercialise limertinib for lung cancer
Yahoo News
over two months ago at simplywall.st         
What Hainan Poly Pharm. Co., Ltds 46 percent Share Price Gain Is Not Telling You
Simply Wall St News at Macroaxis
over two months ago at finance.yahoo.com         
Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update
Yahoo News
over two months ago at finance.yahoo.com         
Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI ...
Yahoo News
over two months ago at finance.yahoo.com         
Actylis Acquires Pharm-Rx, a Leading Value-Added Supplier of Specialty Ingredients for the Vitamin, ...
Yahoo News
over two months ago at simplywall.st         
Sam Chun Dang Pharm. Co., Ltd Investors Are Less Pessimistic Than Expected
Simply Wall St News at Macroaxis
over two months ago at simplywall.st         
Individual investors who hold 55 percent of Hainan Poly Pharm. Co., Ltd gained 29, insiders profited...
Simply Wall St News at Macroaxis
over two months ago at simplywall.st         
Tibet AIM Pharm. Inc.s Financials Are Too Obscure To Link With Current Share Price Momentum Whats In...
Simply Wall St News at Macroaxis
over two months ago at www.macroaxis.com         
Acquisition by Zarrabian Saiid of 11891 shares of Kintara Therapeutics at 0.5902 subject to Rule 16b...
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Kintara Therapeutics that are available to investors today. That information is available publicly through Kintara media outlets and privately through word of mouth or via Kintara internal channels. However, regardless of the origin, that massive amount of Kintara data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Kintara Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Kintara Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Kintara Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Kintara Therapeutics alpha.

Kintara Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.
09/09/2024
2
Tetra Pharm Technologies Relocates to Copenhagen Towers
09/18/2024
3
Amphastar Pharm Sees Composite Rating Climb To 97
09/19/2024
4
Kintara Therapeutics modifies merger terms with TuHURA Biosciences - Investing.com India
09/26/2024
5
Individual investors who hold 55 percent of Hainan Poly Pharm. Co., Ltd gained 29, insiders profited as well
10/04/2024
6
Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer
10/08/2024
7
IBD Rating Upgrades Amphastar Pharm Flashes Improved Relative Price Strength
10/15/2024
8
Amphastar Pharm Joins Elite List Of Stocks With 95-Plus Composite Rating
10/17/2024
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Other Consideration for investing in Kintara Stock

If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account